Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

PRIORITIZE Study Team

doi:10.1016/j.cgh.2022.01.059

Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

PRIORITIZE Study Team

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	546-548.e4
Journal	Clinical Gastroenterology and Hepatology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.cgh.2022.01.059
State	Published - Feb 2023

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.1016/j.cgh.2022.01.059

Cite this

@article{e52bf517db9f4fabbbf6fce0fdb71827,

title = "Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study",

author = "{PRIORITIZE Study Team} and Lok, {Anna S.} and Juhi Moon and Sherman, {Kenneth E.} and Mandana Khalili and Dawn Fishbein and Reddy, {K. Rajender} and Giuseppe Morelli and Joy Peter and Nelson, {David R.} and Brian Pearlman and Larry Michael and Fried, {Michael W.} and Segal, {Jodi B.} and Sulkowski, {Mark S.}",

note = "Funding Information: Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health. Funding Information: Conflicts of interest These authors disclose the following: Anna S. Lok reports grant funding from Bristol-Myers Squibb; and serves on the advisory board for Gilead, and HCV-TARGET. Kenneth E Sherman reports grants/contracts (paid to institution) by AbbVie, Gilead, Intercept, and Zydus; serves on the advisory board and performs consulting for Gilead and Theratechnologies; and is on the DSMB/adjudication committees for Inovio, MedPace, and Horizon. Mandana Khalili reports grant funding from Gilead Sciences Inc and Intercept Pharmaceuticals; and is a consultant for Gilead Sciences Inc. Dawn Fishbein reports grants from Gilead Focus partnership (past) and Gilead Sciences Inc; owns stock in AbbVie and Merck over the years <$10,000 has been held in discretionary account without any personal authority to buy or sell any stock position; however, her father and brother are the portfolio managers; and served on the Gilead Advisory Board for 2020. K. Rajender Reddy reports grants from Gilead, Intercept, Exact Sciences, HCC-TARGET, HCV-TARGET, NASH-TARGET, Mallinckrodt, Bristol-Myers Squibb, Sequana, and Grifols; reports personal fees from Spark Therapeutics, Novo Nordisk, and Mallinckrodt; and is on the DSMB for Novartis. Brian Pearlman reports grants from AbbVie, Merck, and Gilead; is a consultant for AbbVie, Merck, and Gilead; has done sponsored lectures and received honoraria for AbbVie, Merck, and Gilead. Michael W. Fried reports grants from AbbVie, Bristol-Myers Squibb, Merck, and Gilead; reports personal fees from AbbVie, Bristol-Myers Squibb, Merck, and Roche; reports personal fees and other from TARGET PharmaSolutions, outside the submitted work; reports research grants from the National Institutes of Health; and is a stockholder of TARGET PharmaSolutions. Joy Peter reports that her domestic partner is an AbbVie Stockholder. Jodi B. Segal reports grant funding from the National Institutes of Health, National Institute of Health Care Management, Arnold Foundation, and the United States Food and Drug Administration; is an employee at Johns Hopkins University; and is a contractor for the American College of Physicians. Mark S. Sulkowski reports funds paid to Johns Hopkins University by AbbVie, Assembly Biosciences, Janssen; and is a consultant for AbbVie, Gilead, Antios, GSK, and Assembly Biosciences. David R. Nelson reports grants from AbbVie, Gilead and Merck during the conduct of the study; and is a stockholder of TARGET PharmaSolutions. Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health.",

year = "2023",

month = feb,

doi = "10.1016/j.cgh.2022.01.059",

language = "English (US)",

volume = "21",

pages = "546--548.e4",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

AU - PRIORITIZE Study Team

AU - Lok, Anna S.

AU - Moon, Juhi

AU - Sherman, Kenneth E.

AU - Khalili, Mandana

AU - Fishbein, Dawn

AU - Reddy, K. Rajender

AU - Morelli, Giuseppe

AU - Peter, Joy

AU - Nelson, David R.

AU - Pearlman, Brian

AU - Michael, Larry

AU - Fried, Michael W.

AU - Segal, Jodi B.

AU - Sulkowski, Mark S.

N1 - Funding Information: Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health. Funding Information: Conflicts of interest These authors disclose the following: Anna S. Lok reports grant funding from Bristol-Myers Squibb; and serves on the advisory board for Gilead, and HCV-TARGET. Kenneth E Sherman reports grants/contracts (paid to institution) by AbbVie, Gilead, Intercept, and Zydus; serves on the advisory board and performs consulting for Gilead and Theratechnologies; and is on the DSMB/adjudication committees for Inovio, MedPace, and Horizon. Mandana Khalili reports grant funding from Gilead Sciences Inc and Intercept Pharmaceuticals; and is a consultant for Gilead Sciences Inc. Dawn Fishbein reports grants from Gilead Focus partnership (past) and Gilead Sciences Inc; owns stock in AbbVie and Merck over the years <$10,000 has been held in discretionary account without any personal authority to buy or sell any stock position; however, her father and brother are the portfolio managers; and served on the Gilead Advisory Board for 2020. K. Rajender Reddy reports grants from Gilead, Intercept, Exact Sciences, HCC-TARGET, HCV-TARGET, NASH-TARGET, Mallinckrodt, Bristol-Myers Squibb, Sequana, and Grifols; reports personal fees from Spark Therapeutics, Novo Nordisk, and Mallinckrodt; and is on the DSMB for Novartis. Brian Pearlman reports grants from AbbVie, Merck, and Gilead; is a consultant for AbbVie, Merck, and Gilead; has done sponsored lectures and received honoraria for AbbVie, Merck, and Gilead. Michael W. Fried reports grants from AbbVie, Bristol-Myers Squibb, Merck, and Gilead; reports personal fees from AbbVie, Bristol-Myers Squibb, Merck, and Roche; reports personal fees and other from TARGET PharmaSolutions, outside the submitted work; reports research grants from the National Institutes of Health; and is a stockholder of TARGET PharmaSolutions. Joy Peter reports that her domestic partner is an AbbVie Stockholder. Jodi B. Segal reports grant funding from the National Institutes of Health, National Institute of Health Care Management, Arnold Foundation, and the United States Food and Drug Administration; is an employee at Johns Hopkins University; and is a contractor for the American College of Physicians. Mark S. Sulkowski reports funds paid to Johns Hopkins University by AbbVie, Assembly Biosciences, Janssen; and is a consultant for AbbVie, Gilead, Antios, GSK, and Assembly Biosciences. David R. Nelson reports grants from AbbVie, Gilead and Merck during the conduct of the study; and is a stockholder of TARGET PharmaSolutions. Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85127318832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127318832&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.01.059

DO - 10.1016/j.cgh.2022.01.059

M3 - Short survey

C2 - 35182741

AN - SCOPUS:85127318832

SN - 1542-3565

VL - 21

SP - 546-548.e4

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -

Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this